清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Intracranial activity of tepotinib in patients (pts) with MET exon 14 ( MET ex14) skipping NSCLC enrolled in VISION.

作者
Jyoti D. Patel,Xiuning Le,Rémi Veillon,Ian Churchill Anderson,Christine M. Bestvina,Ingel Demedts,Marina Chiara Garassino,Julien Mazières,Masahiro Morise,Egbert Frederik Smit,S. Peter Eggleton,Aurora O’Brate,Gordon Otto,Rolf Bruns,Karl-Maria Schumacher,Paul K. Paik
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): 9084-9084 被引量:15
标识
DOI:10.1200/jco.2021.39.15_suppl.9084
摘要

9084 Background: Brain metastases (BMs) are reported in 20–40% of pts with METex14 skipping NSCLC and present a high unmet need with poor prognosis. Tepotinib is a highly selective MET inhibitor that has demonstrated intracranial activity in preclinical MET-driven lung cancer orthotopic BM models, and has high binding in brain tissue with 25% of free tepotinib levels in brain, relative to plasma. In VISION Cohort A (N = 152), tepotinib had robust and durable clinical activity in pts with METex14 skipping NSCLC, with an objective response rate (ORR) of 45% and a median duration of response (mDOR) of 11.1 months. Here, we report the intracranial activity of tepotinib. Methods: In the Phase II VISION study, pts with METex14 skipping NSCLC received 500 mg QD (450 mg active moiety) oral tepotinib. Study eligibility allowed for pts with BM (neurologically stable on symptomatic therapy with stable steroids, and pts with asymptomatic BM). Primary endpoint: systemic OR per RECIST v1.1; subgroup analysis in pts with BM (determined by RECIST v1.1) was predefined. An ad hoc retrospective analysis of brain lesions determined by CT/MRI was conducted by an IRC using Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria, which accounts for pts’ clinical status and steroid use. Responses were determined in pts with ≥1 evaluable post-baseline tumor assessment (due to the retrospective nature and resulting incomplete data, confirmation was not required). For pts with non-measurable lesions per RANO-BM (enhancing and non-enhancing non-target lesions [NTL]), disease control in the brain was defined as non-complete response/non-progressive disease. Data cut-off: July 1, 2020. Results: Based on RECIST v1.1, 23 pts in Cohort A had BM at baseline. Systemic efficacy in pts with BM (ORR 47.8% [95% CI: 26.8, 69.4], mDOR 9.5 months [95% CI: 5.5, not estimable]) was consistent with the overall population. 15 pts were evaluable by RANO-BM; 12 received prior radiotherapy for BM (median 6.4 weeks before tepotinib initiation [range 2.6–44]). Systemic best objective responses (BORs) were partial response (PR, n = 9), stable disease (SD, n = 3), and progressive disease (PD; n = 3). Of 7 pts with measurable CNS disease per RANO-BM (all of whom received prior radiotherapy), intracranial BORs were PR (n = 5; including 3 with complete disappearance of target lesions), SD (n = 1) and PD (n = 1). Of 8 pts with NTL only, 7 achieved intracranial disease control and 1 had PD. Of the 7 pts with disease control, 3 had CR of the enhancing NTL. Conclusions: Tepotinib demonstrated robust systemic activity in pts with METex14 skipping NSCLC with BM; this is complemented by intracranial activity in an ad hoc analysis using RANO-BM. Small pt numbers, a large proportion of pts with prior radiotherapy for BM, and the retrospective nature of analysis should be considered. Prospective evaluation of intracranial activity data from VISION Cohort C is ongoing. Clinical trial information: NCT02864992.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
贪玩的夏真完成签到,获得积分10
1秒前
科研通AI6.4的应助被xingsixs采纳,获得10
1秒前
风中的世平完成签到,获得积分10
9秒前
Aman完成签到,获得积分10
9秒前
懒得起名字完成签到 ,获得积分10
14秒前
温暖的胜完成签到,获得积分10
20秒前
无悔完成签到 ,获得积分0
33秒前
纯真的雁凡完成签到,获得积分10
35秒前
柔弱的铅笔完成签到,获得积分10
37秒前
Tracy发布了新的文献求助10
43秒前
48秒前
顺利夏云完成签到,获得积分10
1分钟前
xingsixs发布了新的文献求助10
1分钟前
Tracy完成签到,获得积分10
1分钟前
zwlei完成签到,获得积分10
1分钟前
腼腆的雪珊完成签到,获得积分10
1分钟前
热情的衬衫完成签到,获得积分10
1分钟前
xingsixs完成签到,获得积分10
1分钟前
危机的白凡完成签到,获得积分10
1分钟前
徐伟业完成签到 ,获得积分10
1分钟前
RetchieLi完成签到,获得积分10
1分钟前
1分钟前
无限幻枫发布了新的文献求助10
1分钟前
眼睛大的向彤完成签到,获得积分10
1分钟前
俭朴映寒完成签到,获得积分10
2分钟前
汉堡包的应助被bluemoon采纳,获得10
2分钟前
2分钟前
王磊磊0811发布了新的文献求助10
2分钟前
害羞傲安完成签到,获得积分10
2分钟前
外向夜阑完成签到,获得积分10
2分钟前
LINDENG2004完成签到 ,获得积分10
2分钟前
年轻千萍完成签到,获得积分10
2分钟前
睡不醒完成签到 ,获得积分10
2分钟前
简单的不平完成签到,获得积分10
3分钟前
一个爱打乒乓球的彪完成签到 ,获得积分10
3分钟前
单身的涫完成签到,获得积分10
3分钟前
闪闪小凡完成签到,获得积分10
3分钟前
孝顺的冰姬完成签到,获得积分10
3分钟前
拼搏愚志完成签到,获得积分10
3分钟前
田田完成签到 ,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158937
求助须知:如何正确求助?哪些是违规求助? 9554526
关于积分的说明 21719385
捐赠科研通 7748487
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552013
邀请新用户注册赠送积分活动 2471370